Atopic Dermatitis
Consider other triggers beyond food in treating atopic dermatitis
LOUISVILLE, Ky. — Patients may worry about how food allergens impact atopic dermatitis, but there often is more to the story, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Safety data supports ruxolitinib for long-term treatment of atopic dermatitis
Ruxolitinib cream demonstrated efficacy and tolerability in patients with atopic dermatitis during 44 weeks of as-needed treatment, according to two phase 3 trials.
Roflumilast cream safe, effective in mild to moderate atopic dermatitis
Roflumilast cream was an effective and safe treatment for mild to moderate atopic dermatitis in adults and children aged 6 years and older, Arcutis Biotherapeutics announced in a press release.
Dupilumab levels may be unrelated to treatment response, safety in atopic dermatitis
Serum dupilumab levels showed no correlation to treatment response or adverse events in patients with atopic dermatitis during the first year of treatment, according to a study.
No cancer risk seen with topical calcineurin inhibitors for atopic dermatitis
LOUISVILLE, Ky. — Researchers showed with moderate certainty that topical calcineurin inhibitors did not increase cancer risk when used as a treatment for atopic dermatitis among infants, children and adults, according to study results.
VIDEO: ‘There’s something for everybody’ at ACAAI Annual Scientific Meeting
LOUISVILLE, Ky. — In this Healio exclusive, Brian T. Kelly, MD, MA, FACAAI, program chair of the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, highlights key sessions and themes of this year’s meeting.
Asthma diagnosis rates fall among children during COVID-19 pandemic
The numbers of new cases of childhood asthma significantly fell during the COVID-19 pandemic in Japan, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.
Vtama safe, effective with minimal systemic exposure in children with atopic dermatitis
Dermavant Sciences announced positive results from its maximal usage study of Vtama cream in the treatment of atopic dermatitis for children aged as young as 2 years, according to a company press release.
Safety data show Adbry well tolerated in treatment of moderate to severe atopic dermatitis
The results of pooled safety data for Adbry showed positive effects in the prolonged treatment of moderate to severe atopic dermatitis, according to a study.
Upadacitinib has ‘favorable’ benefit-risk profile for atopic dermatitis
Upadacitinib was well tolerated with no new important safety risks among patients with moderate to severe atopic dermatitis treated for approximately 1 year, according to a study published in The Journal of Allergy & Clinical Immunology.